Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday

U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。